Retrospective study to evaluate the outcome of second-line immune checkpoint blockade (ICB) after progression on dual BRAF and MEK inhibition in stage IV melanoma
Latest Information Update: 22 Jun 2019
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 22 Jun 2019 New trial record
- 15 Jun 2019 Results published in the European Journal of Cancer